|
Market Closed -
Nasdaq
02:30:00 17/11/2026 am IST
|
5-day change | 1st Jan Change | ||
| 1.600 USD | -1.84% |
|
-4.19% | -50.46% |
| 13/11 | TD Cowen Initiates Coverage on Alaunos Therapeutics With Buy Rating | MT |
| 16/10 | Top Premarket Gainers | MT |
Company Valuation: Alaunos Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 234 | 155.4 | 16.98 | 4.065 | - | - |
| Change | - | -33.56% | -89.08% | - | - | - |
| Enterprise Value (EV) | 234 | 155.4 | 16.98 | 4.065 | 4.065 | 4.065 |
| Change | - | -33.56% | -89.08% | - | 0% | 0% |
| P/E | -2.95x | -3.82x | -0.48x | -8x | -0.71x | -0.33x |
| PBR | - | - | - | - | - | - |
| PEG | - | 0.1x | 0x | - | -0x | -0x |
| Capitalization / Revenue | 588x | 53.2x | 3,396x | - | - | - |
| EV / Revenue | 0x | 0x | 0x | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0.2x | -0.07x | -0.03x |
| EV / FCF | -0x | - | - | -0.24x | -0.08x | -0.03x |
| FCF Yield | -27.7% | - | - | -418% | -1,279% | -2,878% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -55.5 | -25.5 | -22 | -0.2 | -2.25 | -4.8 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 0.398 | 2.922 | 0.005 | - | - | - |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -73.31 | -35.1 | -34.27 | -20 | -60 | -130 |
| Net income 1 | -78.75 | -37.73 | -35.14 | -17 | -45 | -120 |
| Net Debt | - | - | - | - | - | - |
| Reference price 2 | 163.500 | 97.365 | 10.605 | 1.600 | 1.600 | 1.600 |
| Nbr of stocks (in thousands) | 1,431 | 1,596 | 1,601 | 2,540 | - | - |
| Announcement Date | 30/03/22 | 07/03/23 | 01/04/24 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 40.65L | ||
| 17.13x | 6.55x | 12.55x | 1.74% | 6.56TCr | ||
| 32.67x | 8.73x | 28.87x | 0.07% | 6.04TCr | ||
| 38.83x | 6.91x | 20.67x | 0.84% | 5.58TCr | ||
| 44.13x | 6.17x | 29.36x | -.--% | 4.7TCr | ||
| 34.55x | 3.29x | 14.19x | -.--% | 4.36TCr | ||
| -19.98x | 53.61x | -21.71x | -.--% | 3.61TCr | ||
| 36.23x | 8.96x | 23.37x | 0.36% | 3.67TCr | ||
| 41.91x | 8.08x | 27.1x | -.--% | 3.29TCr | ||
| -74.98x | 14.21x | -76.38x | -.--% | 2.7TCr | ||
| Average | 16.72x | 12.95x | 6.45x | 0.33% | 4TCr | |
| Weighted average by Cap. | 21.75x | 11.58x | 11.42x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- TCRT Stock
- Valuation Alaunos Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
















